Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

EOC Pharma Raises $71 Million in C Round for China Development of In-Licensed Oncology Drugs

publication date: Dec 2, 2019

EOC Pharma, the oncology development arm of China in-licensing company Eddingpharm, raised $71 million in a Series C round led by Tigermed, TF Capital and Yingke PE. Headquartered in Taizhou, EOC manufactures and commercializes oncology products for China use that require mid to late stage clinical development for registration. It currently has a pipeline of six novel products from global biopharmas, including its most recent in-licensing, a Shionogi HER2/EGFR inhibitor intended to treat brain metastasis in advanced metastatic breast cancer patients. Two years ago, EOC completed a $32 million B financing. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.